| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Human pluripotent stem cells (hPSCs) are a promising source of regenerative material for clinical applications. However, hPSC transplant therapies pose the risk of teratoma formation and malignant transformation of undifferentiated remnants. Researchers have recently embarked on studies aimed at locating and directly treating hPSC-derived tumorigenic cells. In particular, novel approaches to directly killing tumorigenic cells are expected to improve the safety of hPSC-based therapy.
Here, we developed a novel method for efficiently generating diverse tumorigenic cell-targeting lentiviral vectors(TC-LVs), which can specifically and efficiently kill tumorigenic cells in transduced hPSCs. This study demonstrates the utility of this methodology and reveals that the products, including hPSCs with the suicide gene downstream of the tumor specific promoter, should pave the way toward safe clinical applications of hPSC-based regenerative medicine.
|
